AKT1 and prostate carcinoma: AZD5363 inhibits phosphorylation of AKT substrates GSK3β and PRAS40 and the downstream biomarker S6 in cell lines, including LNCaP prostate cancer cells and rodent xenografts including from PC3 prostate cancer cells.